Patients’ self-reported adherence to capecitabine on XELOX treatment in metastatic colorectal cancer: findings from a retrospective cohort analysis

Figures & data

Table 1 Baseline patient characteristics

Characteristics	Patients (n=242)	%
Sex
Male	144	59.5
Female	98	40.5
Age, years
Median	63
Range	27–86
ECOG performance status
0	225	92.9
1	17	7.1
2	0	0
Primary tumor site
Colonic	128	52.9
Rectal	88	36.3
Cecal	15	6.2
Appendiceal	11	4.5
Chemotherapy
XELOX + bevacizumab	162	66.9
XELOX	80	33.1

Abbreviations: ECOG, Eastern Cooperative Oncology Group; XELOX, capecitabine plus oxaliplatin.

Figure 1 Capecitabine adherence rate on XELOX treatment.

Notes: Adherence rate with capecitabine during cycles 1–8; Adherence to capecitabine was checked by pharmacists via the patients’ self-reported treatment diaries at a pharmaceutical outpatient clinic; The reason for the number of patients decreasing through the cycles is deviation from XELOX therapy.
Abbreviation: XELOX, capecitabine plus oxaliplatin.

Figure 2 Factors reducing adherence to capecitabine on XELOX treatment (n=1,561).

Note: Factors reducing adherence to capecitabine during cycles 1–8.
Abbreviation: XELOX, capecitabine plus oxaliplatin.

Figure 3 Missed-dose rates with capecitabine.

Figure 4 Effect of age on adherence to capecitabine.

Notes: Adherence to capecitabine in the first cycle, by patient age. In the ≥80 years group (n=6), there were 135 doses of capecitabine taken (168 recommended); 1,474 doses were taken (1,568 recommended) in the 70–80 years group (n=56); 4,725 doses were taken (5,040 recommended) in the <70 years group (n=180); *P<0.001 compared with the 70–80 years group; **P<0.001 compared with the <70 years group.